Abstract
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.
Original language | English (US) |
---|---|
Pages (from-to) | 751-758 |
Number of pages | 8 |
Journal | Expert Opinion on Drug Safety |
Volume | 5 |
Issue number | 6 |
DOIs | |
State | Published - Nov 1 2006 |
Externally published | Yes |
Keywords
- Anidulafungin
- Echinocandin
- Fungi
- Glucan synthase inhibitor
ASJC Scopus subject areas
- Pharmacology (medical)